Formation Bio

AI Drug Discovery

ASN008 Clin2 atopic dermatitis, notalgia paresthetica; Sprifermin Clin2 Knee Osteoarthritis

TrialSpark (Formation Bio) is automating and streamlining the clinical trial process. TrialSpark’s approach to improving clinical trial efficiency is simple: acquire undervalued clinical stage drugs from Pharma and Biotech, use their tech-driven development engine to develop drugs faster and move them more efficiently through clinical trials. The tech-driven platform saves 1-3+ years (and therefore significant cost) per drug program. TrialSpark’s development model makes use of their in-house drug development team streamlining multiple programs at once and clinical expertise in cardiology, dermatology, rheumatology and neurology. However, TrialSpark maintains a strong focus on partnership to advance development of new and better therapies. Current partners include Pfizer and Novartis.